What is the market's earnings forecast for Adaptive next quarter?

Did Adaptive beat or miss consensus estimates last quarter?

What were the key takeaways from Adaptive's earnings call?

What factors drove the changes in Adaptive's revenue and profit?

What is Adaptive's latest dividend and current dividend yield?

What were the key takeaways from Adaptive’s earnings call?

What is the revenue and EPS growth rate for Adaptive year over year?

What is Adaptive's gross profit margin?

- **Record Revenue Growth**: 55% YoY total revenue growth ($277 million) driven by 46% MRD expansion and 17% IM revenue increase.
- **Profitability Milestone**: First-year positive adjusted EBITDA ($12.2 million) and $227 million cash balance.
- **MRD Margin Expansion**: 66% sequencing gross margin (up 13pts YoY) from NovaSeq X Plus adoption and cost efficiencies.
- **2026 Outlook**: Target 22% MRD revenue growth, $1,400/test ASP, and full-year positive EBITDA/free cash flow.
- **IM Monetization**: $15-20 million net cash burn in 2026 with focus on data partnerships (Pfizer) and AI/ML modeling.

**【CEO Summary Section】**
- **2025 Performance Highlights**: Total revenue grew 55% YoY to $277 million, with MRD revenue up 46% and Immune Medicine (IM) revenue up 17%. Adjusted EBITDA turned positive at $12.2 million, up from a loss of $80.4 million in 2024. Cash balance ended the year at $227 million.
- **MRD Growth Drivers**: ClonoSEQ clinical testing volume reached 30,038 tests in Q4 (43% YoY growth), driven by blood-based testing (47% of total) and community penetration (33% of volume). ASP increased 17% YoY to $1,307/test, with Q4 ending at $1,350/test.
- **Strategic Initiatives**: Launched NovaSeq X Plus to improve margins, secured Medicare coverage for MCL recurrence monitoring, and expanded EMR integrations to 173 accounts (40% of ordering volume). IM business signed 2 data partnerships with Pfizer and completed a preclinical study for an ankylosing spondylitis antibody program.

**【CFO Financial Commentary】**
- **2025 Financial Results**: Sequencing gross margin improved to 66% (from 53% in 2024) due to NovaSeq X Plus cost efficiencies. Operating expenses grew 4% YoY, driven by MRD sales & marketing investments. Full-year MRD revenue was $212 million (including $19.5 million in milestones), with pharma revenue up 20% YoY.
- **2026 Guidance**: MRD revenue expected to grow 22% YoY to $255-265 million (excluding milestones). Target ASP of $1,400/test in 2026. Full-year operating expenses projected at $350-360 million, with plans for positive adjusted EBITDA and free cash flow.

**【Q&A Key Highlights】**
- **Volume Growth Drivers**: Blood-based testing expected to exceed 50% of MRD volume in 2026, with community testing targeting >35% of volume. Flatiron EMR integration and serial testing protocols are key growth levers.
- **ASP Outlook**: 2026 target of $1,400/test based on 2 large payer contract renegotiations. Sequential ASP growth expected to accelerate in H2/2026.
- **Competitive Landscape**: ClonoSEQ maintains 5-7x sensitivity advantage over flow cytometry assays in myeloma. Community adoption and reimbursement coverage mitigate competitive threats.
- **IM Business Strategy**: Focused on data monetization (Pfizer partnerships) and reducing cash burn to $15-20 million in 2026. No immediate plans for additional antibody programs beyond TCR-antigen data generation.

Adaptive Biotechnologies Corporation (ADPT) Q4 2025 Earnings Call Transcript

- **Revenue Surge**: Q3 revenue of $94 million (+102% YoY), MRD revenue at $56.8 million (+52% YoY), driven by 38% test volume growth and $1,340 ASP.
- **Profitability Breakthrough**: MRD business turned cash flow positive with $7 million EBITDA, sequencing gross margin up to 66%.
- **Strategic Wins**: First commercial payer coverage in DLBCL, NCCN CLL guideline updates, and $200 million MRD Pharma backlog.
- **Updated Guidance**: Full-year MRD revenue raised to $202-$207 million, cash burn reduced to $45-$50 million.
- **Growth Drivers**: Blood-based testing at 45%, community volume at 31%, and 11 new EMR integrations boosting serial testing.

**【CEO Summary Section】**
- **Revenue Growth and Profitability**: Total revenue reached $94 million (102% YoY growth), with MRD revenue at $56.8 million (52% YoY). Adjusted EBITDA for MRD business turned positive at $7 million, achieving cash flow positivity ahead of plan. Sequencing gross margin improved to 66% (10% YoY increase) due to NovaSeq X Plus adoption and volume leverage.
- **Clinical Volume Expansion**: ClonoSEQ tests grew 38% YoY to 27,111, with US ASP rising 28% to $1,340. Blood-based testing reached 45% of volume, exceeding the full-year goal. Community-based testing contributed 31% of volume, up from 20% pre-Flatiron integration.
- **Strategic Wins**: NCCN guidelines updated for CLL, incorporating MRD-guided treatment. First commercial payer coverage in DLBCL and expanded CLL coverage (260 million lives). Total backlog for MRD Pharma stood at $200 million.
- **Updated Guidance**: Full-year MRD revenue raised to $202-$207 million (39%-42% YoY growth), with cash burn reduced to $45-$50 million.

**【CFO Financial Commentary】**
- **Financial Highlights**: GAAP net income of $9.5 million, Non-GAAP EPS of $1.08. Total company gross margin (excluding Genentech) was 70%, driven by 66% sequencing gross margin. Operating expenses stabilized sequentially at $83.7 million, with cash burn down 51% YoY to $24.2 million.
- **Segment Performance**: MRD adjusted EBITDA of $7 million (vs. -$6.1 million YoY). Immune medicine EBITDA deficit narrowed to $10 million (vs. -$8.7 million YoY). Total company cash position of $217 million.
- **Guidance Tightening**: Full-year operating expenses reduced to $335-$340 million, reflecting cost discipline. MRD cash burn expected at 15% of revenue, with immune medicine at $25-$30 million.

**【Q&A Key Highlights】**
- **MRD Pharma Backlog**: $200 million backlog to be recognized over 5-7 years, with 2025 CLL bookings doubling YoY. FDA endpoint qualification efforts in CLL and DLBCL expected to drive future growth.
- **ASP Trends**: Q3 ASP of $1,340 on track to meet $1,300+ target, with long-term goal of $1,700-$1,800. Coverage wins in DLBCL and CLL support ASP expansion.
- **EMR Integration Impact**: 11 new EMR integrations (7 academic, 4 community), with integrated accounts contributing 24% of community volume (vs. 20% pre-launch). Serial testing orders in Flatiron accounts grew 17% QoQ.
- **Community Penetration**: 30% of volume from community settings, with 65 sales reps focused on community expansion. Blood-based testing reached 45% of total volume, up 3-4% YoY in myeloma and ALL.
- **Future Investments**: $25-$30 million annual cash burn for immune medicine R&D, balanced against MRD profitability. Focus on TCR antigen prediction models and T-cell depletion antibody pipeline.

Adaptive Biotechnologies Corp (ADPT) Q3 2025 Earnings Call Transcript

- **MRD Business Breakthrough**: Q2 MRD EBITDA positive ($1.9M) vs loss last year; full-year revenue guide raised to $190-200M. 
- **Volume Surge**: 25,321 clonoSEQ tests (+37% YoY), 10% sequential growth; blood-based testing at 44% of MRD volume. 
- **Strategic Wins**: Flatiron OncoEMR integration across 113 sites; NeoGenomics partnership to expand into 60% new accounts. 
- **Financial Strength**: Cash burn $11M (36% YoY improvement); gross margin 64% (vs 50% YoY). 
- **Pharma Growth**: $218M backlog (+21% YoY); 90 studies use clonoSEQ as primary endpoint. 
- **Regulatory Momentum**: CHMP positive opinion for MRD as endpoint; MIDAS trial shows MRD-negative patients can avoid transplant. 


**【CEO Summary Section】**
- **MRD Business Milestones**: Achieved $2 million positive adjusted EBITDA in Q2, up 42% YoY in revenue. MRD profitability ahead of schedule, with $190-200M full-year guidance raised. 
- **Clinical Volume Growth**: 25,321 clonoSEQ tests delivered (+37% YoY), 10% sequential increase. Blood-based testing at 44% of MRD volume, up 40% YoY. 
- **Strategic Collaborations**: Flatiron OncoEMR integration across 113 community sites; NeoGenomics partnership to expand into 60% new accounts. 
- **Regulatory & Clinical Momentum**: CHMP positive opinion for MRD as early endpoint in myeloma; MIDAS trial shows MRD-negative patients can avoid transplant. 

**【CFO Financial Commentary】**
- **Topline Performance**: Q2 revenue $58.9M (+36% YoY), MRD revenue $49.9M (+42% YoY). Sequencing gross margin 64% (vs 50% YoY). 
- **Profitability**: MRD adjusted EBITDA $1.9M vs -$11.3M YoY. Total company cash burn $11M (36% YoY improvement). 
- **Updated Guidance**: Full-year MRD revenue raised to $190-200M (+31-37% YoY); cash burn lowered to $45-55M. 
- **Milestone Revenue**: Anticipate $14-15M in MRD milestones vs prior $8-9M. 

**【Q&A Highlights】**
- **EMR Integration Impact**: Epic-integrated sites grow 2x faster; Flatiron serial testing feature driving repeat orders. 40% of MRD volume now through EMR. 
- **Pricing Momentum**: U.S. ASP $1,290 (+17% YoY); 8 key payer contracts closed YTD. 
- **Pharma Pipeline**: $218M backlog (+21% YoY); 90 studies use clonoSEQ as primary/secondary endpoint. 
- **International Expansion**: CHMP opinion validates MRD as endpoint; exploring European MRD commercialization. 
- **Cash Flow Outlook**: MRD business on path to recurring EBITDA profitability; NovaSeq X scaling to improve margins. 


Adaptive Biotechnologies Corporation (ADPT) Q2 2025 Earnings Call Transcript

- **MRD Growth Accelerates**: 34% YoY revenue rise, 36% test volume increase, 14% ASP hike, 17ppt gross margin expansion.
- **EMR Integration Payoff**: Top 10 EMR-integrated accounts grow 27% QoQ, 6/7 long-term accounts >75% YoY growth.
- **Medicare Expansion**: MCL Medicare coverage and enhanced assays drive 12% NHL contribution (vs. 10% YoY).
- **Cash Position Strength**: $233M cash, 38% Q1 cash burn reduction, full-year burn guide lowered to $50-60M.
- **NovaSeq X Impact**: H2 launch targeting 70%+ gross margin at scale.

**【CEO Summary Section】**
- MRD revenue grew 34% YoY to $43.7 million, driven by 36% increase in clonoSEQ test volume and 14% ASP growth.
- Medicare coverage expansion in MCL and enhanced EMR integrations (27 live, 5+ top 10 accounts) accelerated community testing growth (+42% YoY).
- Sequencing gross margin improved 17ppt to 62%, with cash burn down 38% to $23 million Q1.
- Full-year guidance raised: MRD revenue $180-190M (vs. prior $175-185M), operating expenses $335-345M (vs. $340-350M), cash burn $50-60M (vs. $60-70M).

**【CFO Financial Commentary】**
- Total revenue $52.4M (+25% YoY), with 83% from MRD (clini: 65%, pharma: 35%).
- MRD pharma revenue +7% YoY to $15.2M, including $4.5M milestones.
- Adjusted EBITDA loss narrowed 76% to $4.1M (MRD) and 21% to $3.3M (Immune Med).
- NovaSeq X launch in H2 expected to drive 5-8ppt gross margin improvement.

**【Q&A Key Highlights】**
- **Market Growth Drivers**: Lymphoma (DLBCL/MCL) volumes +27% QoQ in EMR-integrated top 10 accounts; blood-based testing now 44% of U.S. MRD volume (vs. 39% YoY).
- **EMR Integration Impact**: 6/7 long-term integrated accounts saw >75% YoY growth; EMR-enabled accounts outperformed non-integrated by 10-15ppt.
- **Technology Advancements**: Enhanced DLBCL assay sensitivity (7x) driving pharma trial adoption; NeoGenomics partnership Phase 1 launch in H2.
- **Financial Discipline**: 9% YoY opex decline; 2025 IM R&D spend capped at $25-30M, partially funded by pharma services growth (+12% Q1).

Adaptive Biotechnologies (ADPT)-1 May 25-2025 Q1 Earnings call transcript

- **Revenue Beat by $200M**: Q3 $12.3B (+18% YoY) driven by cloud/AI
- **$1B AI Investment**: Enterprise-focused generative models
- **FY24 Outlook**: 15-17% CAGR, H2 gross margin 62-64%
- **Key Metrics**: 70% AI in new contracts, 40% cloud market share
- **Risk Management**: 15% US pricing, 80% FX hedged

**【CEO Opening Remarks】**
- Q3 revenue reached $12.3B, up 18% YoY, exceeding guidance by $200M.
- North America (+22% YoY) and EMEA (+16% YoY) led growth, driven by cloud infrastructure and AI solutions.
- Announced $1B investment in generative AI R&D, targeting enterprise use cases.
- FY24 outlook: 15-17% revenue CAGR, with H2 gross margin expansion to 62-64%.

**【CFO Financial Highlights】**
- GAAP EPS: $1.25 (vs. $1.10 consensus)
- Free cash flow: $3.8B (up 12% YoY)
- Operating expenses: $4.2B (+7% YoY), with 80% allocated to R&D
- Cloud ARR: $28.5B (up 20% YoY)

**【Q&A Key Takeaways】**
1. **AI Adoption**: 70% of new enterprise contracts now include generative AI tools
2. **Competitive Position**: 40%+ market share in hybrid cloud infrastructure
3. **Risk Mitigation**: 15%+ pricing in US, hedging 80% of FX exposure
4. **Long-Term Vision**: Targeting $50B ARR by FY28, with AI contributing 30%+

Adaptive Biotechnologies Corporation (ADPT) Q4 2024 Earnings Call Transcript

Adaptive Biotechnologies (ADPT)-7 Nov 24-2024 Q3 Earnings call transcript

Adaptive Biotechnologies (ADPT)-1 Aug 24-2024 Q2 Earnings call transcript

Adaptive Biotechnologies (ADPT)-7 May 24-2024 Q1 Earnings call transcript

Adaptive Biotechnologies (ADPT)-14 Feb 24-2023 Q4 Earnings call transcript

- **Strategic Review Initiated**: Adaptive Biotechnologies embarks on strategic review with Goldman Sachs to optimize MRD and Immune Medicine businesses.
- **MRD Growth Momentum**: Q3 clonoSEQ volumes up 56% YoY, ASPs growing mid-single digits sequentially, with 2025 profitability target.
- **Immune Medicine Transition**: Shifts to drug discovery model with novel MS target identified, validating AI-driven platform.
- **Financial Discipline**: 2023 MRD revenue guidance of $100-105 million, excluding Immune Medicine from total metrics.
- **Cost Optimization**: Lab move and NovaSeq sequencing transition to enhance margins, with 2024 LIMS overhaul and 2025 cost savings.

**【CEO Summary Section】**
- Adaptive Biotechnologies is undergoing a strategic review with Goldman Sachs to maximize value of its two distinct businesses: MRD (Molecular Residual Disease) and Immune Medicine.
- MRD business achieved 56% year-over-year growth in clonoSEQ test volumes (15,072 tests) and 3% ASP growth sequentially, driven by improved payer mix and operational efficiency.
- Immune Medicine transitioned to a drug discovery model, with a novel MS target identified and validation of its AI-driven target discovery platform.
- The company updated guidance to exclude Immune Medicine revenue from total company metrics, focusing on MRD profitability by 2025.

**【CFO Financial Commentary】**
- Q3 2023 total revenue: $37.9 million (65% MRD, 35% Immune Medicine).
- MRD clinical revenue grew 24% YoY to $24.7 million, offsetting 4% decline in MRD Pharma due to biopharma macro headwinds.
- Gross margin: 49% (down 100 bps YoY due to lab move costs and lower Genentech amortization).
- Updated MRD revenue guidance: $100-105 million for 2023, with ASPs expected to grow mid-single digits in Q4.
- Full-year OpEx target: ~$375 million (-3% YoY), with cash burn expected to normalize at $35 million in Q4.

**【Q&A Key Highlights】**
- **Strategic Separation**: Management emphasized distinct value drivers of MRD (execution-focused) and Immune Medicine (drug discovery), with potential for separate optimization.
- **MRD Outlook**: 50%+ test volume growth YoY, ASPs on track for mid-single-digit Q4 growth, and 2025 profitability target.
- **Immune Medicine**: Novel MS target discovery validates platform, with potential partnerships under evaluation.
- **Cost Efficiency**: Lab move completion and NovaSeq sequencing transition (2024) expected to drive margin expansion.
- **Backlog Strength**: MRD Pharma backlog of $190 million signals future revenue resilience despite near-term pharma spending headwinds.

Actual				-0.25	-0.26	-0.27	-0.33	-0.29	-0.35	-0.4	-0.43	-0.44	-0.37	-0.32	-0.28	-0.4	-0.33	-0.35	-0.48	-0.33	-0.31	-0.22	-0.23	-0.2	-0.17	0.06	-0.09
Forecast				-0.208	-0.2817	-0.2813	-0.2934	-0.4013	-0.4153	-0.4213	-0.4521	-0.4516	-0.4283	-0.363	-0.3468	-0.377	-0.3468	-0.3387	-0.3313	-0.3456	-0.3341	-0.2875	-0.2563	-0.292	-0.2388	-0.1466	-0.1855
Surprise	0.00%	0.00%	0.00%	-20.19%	+7.70%	+4.02%	-12.47%	+27.73%	+15.72%	+5.06%	+4.89%	+2.57%	+13.61%	+11.85%	+19.26%	-6.10%	+4.84%	-3.34%	-44.88%	+4.51%	+7.21%	+23.48%	+10.26%	+31.51%	+28.81%	+140.93%	+51.48%

ADPT

ADPT fundamentals

ADPT Q4 2025 Earnings

Earnings Call

You can ask Aime

ADPT

ADPT fundamentals

ADPT Q4 2025 Earnings

Earnings Call

ADPT Earnings Call Summary for Q4/20254:30 PM on Feb 5, 2026

ADPT Earnings Call Summary for Q3/20254:30 PM on Nov 5, 2025

ADPT Earnings Call Summary for Q2/20254:30 PM on Aug 5, 2025

ADPT Earnings Call Summary for Q1/20254:30 PM on May 1, 2025

ADPT Earnings Call Summary for Q4/20244:30 PM on Feb 11, 2025

You can ask Aime